Authors : Saidu A.; Onuekwusi C. E.; Farouk J. M.; Yanah Y. M.; Abdullahi A. A.; Hassan M. B.; Egwim E. C.

Volume/Issue : Volume 11 - 2026, Issue 2 - February

Google Scholar : https://tinyurl.com/ymwvmfp8

Scribd : https://tinyurl.com/msszbuaz

DOI : https://doi.org/10.38124/ijisrt/26feb815

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Abstract : Cancer is one of the leading causes of mortality worldwide. Systemic toxicities and multi-drug resistance associated with chemotherapies have prompted the discovery and researches towards the development of alternative approaches. Nanotechnology has evolved as a promising approach in cancer studies to make diagnostic more precise, improve therapeutic outcomes by offering a target drug delivery system. Healthy cells damages can be minimized; therapeutic agents can reach specific cells or tissues by bypassing biological barriers through engineered Nanoparticles. Liposomes are selfassembled, uni-lamellar or multi-lamellar spherical vesicles primarily composed of phospholipids from either animal plant or origin. The amphipathic nature of Liposomes makes it possible to encapsulate hydrophilic drugs within the aqueous core and hydrophobic drugs in the lipid bilayer, which protects the drugs from environmental degradation during systemic circulation. Due to the biocompatibility, structural versility, and ability to improve the therapeutic of anticancer agents, liposomes are the most widely investigated nanocarrires in oncology. The impact of liposomes and their applications in cancer therapy were explored in this review.

Keywords : Cancer, Drug Resistance, Liposomes, Nanotechnology, Nanoparticles, Oncology.

References :

1. Ahmed, K.S., Hussein, S.A., Ali, A.H., Korma, S.A., Lipeng, Q., & Jinghua, C. (2019).        Liposome:             composition,     characterisation, preparation, and recent innovation in                clinical applications.           J Drug Target, 27 (7), 742–61.
2. Aminolroayaei, F., Shahbazi-Gahrouei, S., Khorasani, A., & Shahbazi-Gahrouei, D. (2023). A            review of imaging methods and recent nanoparticles for breast cancer diagnosis.       Information, 15(1), 10.
3. An, X., Yu, W., Liu, J., Tang, D., Yang, L., & Chen, X. (2024). Oxidative cell death in cancer:           Mechanisms and therapeutic opportunities. Cell Death Dis., 15, 556.
4. Barenholz, Y. (2012). Doxil®—the first FDA approved nano-drug: lessons learned. J Control            Release, 160 (2), 117-34.
5. Bray, F., Laversanne, M., & Sung, H. (2024). Global cancer statistics 2022: GLOBOCAN   estimates of          incidence and mortality worldwide for 36 cancers in 185 countries. CA               Cancer J Clin., 74 (3), 229-263.
6. Cao, L., Zhu, Y., Wang, W., Wang, G., Zhang, S., & Cheng, H. (2021). Emerging nano-based            strategies against drug resistance in tumor chemotherapy. Front. Bioeng. Biotechnol.,     9, 798882.
7. Cheng, Z., Huang, H., Yin, M., & Liu, H. (2025). Applications of liposomes and lipid           nanoparticles        in cancer therapy: current advances and prospects. Experimental Hematology & Oncology, 14,11.
8. Desai, D., Desai, P., Salokhe, P., Ambuskar, S., & Chavan, O. (2025). Liposomes as Smart Drug        Delivery Vehicles: Advances, Applications, And Future Prospects. International Journal       of Pharmaceutical Sciences, 3 (5), 1170-1183.
9. Johnsen, K.B., Burkhart, A., Thomsen, L.B., Andresen, T.L., & Moos, T. (2019). Targeting the          transferrin receptor for brain drug delivery. Prog Neurobiol., 181, 101665.
10. Kim, K., and Khang, D. (2020). Past, present, and future of anticancer nanomedicine. Int. J.                Nanomedicine, 15, 5719–5743.
11. Large, D.E., Abdelmessih, R.G., Fink, E.A., & Auguste, D.T. (2021). Liposome composition in          drug delivery design, synthesis, characterization, and clinical application. Adv Drug Deliv           Rev., 176, 113851.
12. Li, L.Y., Guan, Y.D., Chen, X.S., Yang, J.M., & Cheng, Y. (2021). DNA repair pathways in               cancer    therapy and resistance. Front. Pharmacol., 11, 629266.       doi:10.3389/fphar.2020.629266
13. Li, X., Wang, Z., Xu, J., & Zhang, X. (2018). Liposomes as drug delivery systems for controlled        release of bioactive agents. J Control Release., 271, 169-182.
14. Mekuye, B., & Abera, B. (2023). Nanomaterials: An overview of synthesis, classification,   characterization, and applications. Nano Select, 4:486–501.
15. Nsairat, H.,  Khater, D., Sayed, U., Odeh, F., Al Bawab, A., & Alshaer, W. (2022). Liposomes:          structure, composition, types, and clinical applications. Heliyon, 13;8(5), e09394.
16. Palange, P.N., (2023). Liposome Based Drug Delivery Systems in Cancer Treatment.            International        Journal of Pharmaceutical Research and Applications, 8(2), 986-1001.
17. Ray, P., Haideri, N., Haque, I., Mohammed, O., Chakraborty, S., & Banerjee, S. (2021). The               impact    of nanoparticles on the immune system: a gray zone of nanomedicine. J.        Immunol.               Sci., 5,    19–33.
18. Rommasi, F., & Esfandiari, N. (2021). Liposomal Nanomedicine: Applications for Drug      Delivery                in Cancer Therapy. Nanoscale Research Letter, 16,95.
19. Sabir, S., Thani, A.S.B., & Abbas, Q. (2025). Nanotechnology in cancer treatment:                revolutionizing     strategies against drug resistance. Front. Bioeng. Biotechnol.,        13:1548588.
20. Salem, S. S., Hammad, E. N., Mohamed, A. A., & El-Dougdoug, W. (2023). A comprehensive           review of nanomaterials: types, synthesis, characterization, and applications. Biointerface Res. Appl. Chem., 13 (1). doi:10.33263/BRIAC131.041
21. Sanna, V., (2014). Nanomedicine and targeted drug delivery in breast cancer. Cancer            Nanotechnology, 28(7), 123-133.
22. Schirrmacher, V., (2019). From chemotherapy to biological therapy: a review of novel concepts         to reduce the side effects of systemic cancer treatment. Int J Oncol., 54 (2), 407–419.
23. Sercombe, L., Veerati, T., Moheimani, F., Wu, S.Y., Sood, A.K., & Hua, S. (2015). Advances            and challenges of liposome assisted drug delivery. Front Pharmacol., 6, 286.
24. Sheoran, S., Arora, S., Samsonraj, R., Govindaiah, P., and vuree, S. (2022). Lipid-based       nanoparticles for treatment of cancer. Heliyon, 8, e09403.
25. Sorriento, D. (2024). Oxidative Stress and Inflammation in Cancer. Antioxidants, 13, 1403. https://doi.org/10.3390/ antiox13111403
26. Wahab, S., Alshahrani, M.Y., Ahmad, M.F., & Abbas, H. (2021). Current trends and future perspectives of nanomedicine for the management of colon cancer. Eur. J. Pharmacol.      910, 174464.
27. Wang, S., Chen, Y., Guo, J., & Huang, Q. (2023). Liposomes for Tumor Targeted Therapy: A             Review. Int. J. Mol. Sci., 24, 2643.
28. Yao, Y., Zhou, Y., Liu, L., Xu, Y., Chen, Q., & Wang, Y. (2020). Nanoparticle-based drug delivery in cancer therapy and its role in overcoming drug resistance. Front. Mol. Biosci.,                 7,193.